[1]周颖 顾宁.基于高尿酸血症与高血压相关性的药物研究进展[J].心血管病学进展,2020,(6):630.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.017]
 ZHOU Ying,GU Ning.Drugs Based on the Relationship Between Hyperuricemia and Hypertension[J].Advances in Cardiovascular Diseases,2020,(6):630.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.017]
点击复制

基于高尿酸血症与高血压相关性的药物研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年6期
页码:
630
栏目:
综述
出版日期:
2020-06-25

文章信息/Info

Title:
Drugs Based on the Relationship Between Hyperuricemia and Hypertension
作者:
周颖1 顾宁12
1.南京中医药大学研究生院,江苏 南京 2100 29;2.南京中医药大学附属南京市中医院心内科,江苏 南京 2100 12)
Author(s):
ZHOU Ying 1 GU Ning12
Graduate School, Nanjing University of Chinese Medicine ,Nanjing 2100 29,Jiangsu,China; 2.Department of Cardiology,Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,Nanjing 210012,Jiangsu,China)
关键词:
高血压高尿酸血症相关药物
Keywords:
Hypertension Hyperuricemia Related drugs
DOI:
10.16806/j.cnki.issn.1004-3934.2020.06.017
摘要:
近年来随着人们生活水平提高,高血压伴高尿酸血症的发病率持续上升,当高血压与高尿酸血症同时存在时,患者发生心、脑和肾等靶器官损害的风险明显上升。为提高高血压伴高尿酸血症的临床诊治水平,现基于原发性高血压与高尿酸血症之间的相互影响,探讨降尿酸药物以及降血压药物对血压、血尿酸水平的影响。
Abstract:
In recent years,with the improvement of people’s living standards,the incidence of hypertension with hyperuricemia continues to rise. when hypertension and hyperuricemia exist at the same time,the risk of heart,brain,kidney and other target organ damage is significantly increased. In order to improve the clinical diagnosis and treatment of hypertension with hyperuricemia,the effects of anti uric acid drugs and antihypertensive drugs on blood pressure and serum uric acid level were discussed based on the interaction between essential hypertension and hyperuricemia

参考文献/References:


[1]黄雨晴,张莹,莫与京,等. 原发性老年高血压患者高尿酸血症患病率的调查研究[J]. 中华老年心脑血管病杂志,2015,17(5):530-531.

[2]Murray K,Burkard T. Hyperuricemia,gout and cardiovascular diseases[J]. Ther Umsch,2016,73(3):141-146.

[3]李静. 高 尿酸血症的流行病学研究[J]. 中国心血管杂志,2016,21(2):83-86.

[4]任燕妮,何雪琴,李微,等. 血浆致动脉硬化指数与原发性高血压患者高尿酸血症、尿微量白蛋白的关系研究[J]. 实用心脑肺血管病杂志,2018,26(7):30-33.

[5]Juraschek SP,Kovell LC,Miller ER,et al. Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout[J]. PloS One,2013,8(2):e56546.

[6]Sánchez-Lozada LG,Soto V,Tapia E,et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia[J]. Am J Physiol Renal Physiol,2008,295(4):F1134-F1141.

[7]寇惠娟,马瑞,高登峰,等. 高 血压患者高尿酸血症与肾损害及血浆致动脉硬化指数的关系[J]. 岭南心血管病杂志,2016,22(4):442-445.

[8]赵力,邹和建,薛愉. 痛风与心血管疾病[J]. 中国实用内科杂志,2018,38(12):1131-1135.

[9]Wang J,Qin T,Chen J,et al. Hyperuricemia and risk of incident hypertension:a systematic review and meta-analysis of observational studies[J]. PloS O ne,2014,9(12):e114259.

[10]Higa S,Shima D,Tomitani N,et al. The effects of topiroxostat on vascular function in patients with hyperuricemia[J]. J Clin Hypertens (Greenwich),2019,21(11):1713-1720.

[11]赵劲东,贾静静,董平栓,等. 别嘌呤醇对高血压患者血压影响的Meta分析[J]. 临床心血管病杂志,2018,34(1):35-41.

[12]El-Bassossy HM, Mahmoud MF, Eid BG. The vasodilatory effect of allopurinol mediates its antihypertensive effect:Effects on calcium movement and cardiac hemodynamics[J].?Biomed Pharmacother,2018,100:381-387.

[13]El-Bassossy HM,Shaltout HA. Allopurinol alleviates hypertension and proteinuria in high fructose,high salt and high fat induced model of metabolic syndrome[J]. Transl Res,2015,165(5):621-630.

[14]蒋兰兰,金星,沈赟,等. 非布司他治疗痛风伴高尿酸血症患者的有效性及安全性[J]. 实用医学杂志,2014,30(17):2827-2830.

[15]付红艳. 非布司他治疗痛风及高尿酸血症的效果及不良反应[J]. 中国医药指南,2019,17(18):132.

[16]Robinson PC ,Dalbeth N . Febuxostat for the treatment of hyperuricaemia in gout[J]. Expert Opin Pharmacother,2018,19(11):1289-1299..

[17]?Zhang M,Solomon DH,Desai RJ,et al. Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol[J]. Circulation,2018,138:1116-1126.

[18]刘灿,黄雨晴,余雪菊,等. 高 龄男性原发性高血压患者高尿酸血症患病率调查及相关因素分析[J]. 中华老年心脑血管病杂志,2016,18(3):251-253.

[19]史进,耿猛. 苯溴马隆在伴有高尿酸血症的老年高血压患者中的疗效及安全性[J]. 中西医结合心血管病电子杂志,2017,5(20):74-75.

[20]Kojima S,Kojima S,Hifumi A,et al. Therapeutic strategy for efficient reduction of serum uric acid levels with allopurinol versus benzbromarone in hyperuricemic patients with essential hypertension — A randomized crossover study (terao study)[J].Int J Cardiol,2016,224:437–439.

[21]Fini MA,Stenmark KR. Pegloticase and lowering blood pressure in refractory gout; is it uric acid or hydrogen peroxide?[J]. Eur J Intern Med,2019,69:e11–e12..

[22]Park SW,Noh HJ,Sung DJ,et al. Hydrogen peroxide induces vasorelaxation by enhancing 4-aminopyridine-sensitive Kv currents through S-glutathionylation[J]. Pflugers Arch,2015,467(2):285–297.

[23]Johnson RJ,Choi HK,Yeo AE, et al. Pegloticase treatment significantly decreases blood pressure in patients with chronic gout[J]. Hypertension,2019,74(1):95–101.

[24]马金魁,张宏斌. 高 尿酸血症及治疗药物的研究进展[J]. 广东医学,2018,39(S2):262-267.

[25]Khanna D,Fitzgerald JD,Khanna PP,et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1:systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia[J]. Arthr Care Res(Hoboken),2012,64(10):1431-1446.

[26]Wolff ML,Cruz JL,Vanderman AJ,et al. The effect of angiotensin II receptor blockers on hyperuricemia[J]. Ther Adv Chronic Dis,2015,6(6):339-346.

[27]Choi HK,Soriano LC,Zhang Y,et al. Antihypertensive drugs and risk of incident gout among patients with hypertension :population based case—control study[J].?BMJ,2012,344:d8190.

[28]袁静,郭艺芳. 利尿剂在降压治疗中的应用[J]. 心血管病学进展,2015,36(6):668-672.

[29]Hueskes BA,Roovers EA,Mantel-Teeuwisse AK,et al. Use of diuretics and the risk of gouty arthritis:a systematic review[J].?Semin Arthritis Rheum,2012,41(6):879-889.

[30]Bao Y,Curhan G,Merriman T,et al. Lack of gene-diuretic interactions on the risk of incident gout:the Nurses’ Health Study and Health Professionals Follow-up Study[J]. Ann Rheum Dis,2015,74(7):1394-1398.

[31] Waller PC,Ramsay LE. Predicting acute gout in diuretic-treated hypertensive patients[J]. J Hum Hypertens,1989,3(6):457-461.

[32] Hunter DJ,York M,Chaisson CE,et al. Recent diuretic use and the risk of recurrent gout attacks:the online case-crossover gout study[J]. J Rheumatol,2006,33(7):1341-1345.

[33] Wilson L,Nair KV,Saseen JJ. Comparison of new-onset gout in adults prescribed chlorthalidone vs. hydrochlorothiazide for hypertension[J]. J Clin Hypertens (Greenwich),2014,16(12):864-868.

[34] El-Sheikh AA,van den Heuvel JJ,Koenderink JB,et al. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter,multidrug resistance protein 4[J]. Br J Pharmacol,2008,155(7):1066-1075.

[35]?McAdams DeMarco MA,Maynard JW,Baer AN,et al. Diuretic use,increased serum urate levels,and risk of incident gout in a population-based study of adults with hypertension:the Atherosclerosis Risk in Communities cohort study[J].?Arthritis Rheum,2012,64(1):121-129.

[36]Nádházi Z,Dézsi CA. The Results of ACES(Antihypertensive Combinations’ Long Term Efficacy Comparing Study):analysis of metabolic effects of antihypertensive combination therapies[J]. Clin Drug Investig,2016,36(10):819-827.

[37]陈鲁原. 从降压联合用药方案的长期疗效比较研究看血管紧张素转换酶抑制剂联合噻嗪样利尿剂的安全性[J]. 中华高血压杂志,2017,25(10):920-923.

[38]Choi HK,Soriano LC,Zhang Y,et al. Antihypertensive drugs and risk of incident gout among patients with hypertension:population based case-control study[J]. BMJ ,2012,344:d8190.

[39]郭韵,王晓非. 痛风的诊治现状及展望[J]. 中国实用内科杂志,2018,38(12):1127-1130.

相似文献/References:

[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
 SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(6):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
 FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(6):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
 CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
 ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(6):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
 ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
 HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(6):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
 ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(6):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
 LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(6):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
 WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(6):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]

更新日期/Last Update: 2020-09-22